RxDoctor Payments Data

Rajendra Mehta, MD

Cardiovascular Disease · Jackson, MINPI 1770549099

Payments from drug & device makers

$42,721in general payments, 2019–2025

Across 30 payments — averaging $1424.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$17K
  • Amgen$9K
  • Novo Nordisk AS$7K
  • Bayer$5K
  • Eli Lilly$4K
  • Medtronic$54
  • plus $214 from 9 others
$387,635in research payments, 2019–2025

Across 210 payments — averaging $1845.88 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Novo Nordisk AS$354K
  • Eli Lilly$32K
  • Regeneron$2K

What the payments were for

  • Food & beverage$282100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$42,721 in reported general payments places this provider in the 85th percentile of 760 cardiovascular disease providers in Michigan.

See all cardiovascular disease providers in Michigan

Medicare billing

Part B allowed, 2024
$479,724
Medicare patients
869
Services billed
5,412

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban290$345,020
XareltoRivaroxaban73$71,248
EntrestoSacubitril/Valsartan49$62,006
BrilintaTicagrelor18$16,022
FarxigaDapagliflozin Propanediol12$9,873
Metoprolol Succinate415$8,041
Atorvastatin Calcium458$7,292
ClopidogrelClopidogrel Bisulfate328$5,774
Diltiazem 24hr Er (Cd)Diltiazem Hcl75$3,823
Diltiazem 12hr ErDiltiazem Hcl12$3,005
Amiodarone Hcl68$2,571
Lisinopril295$2,273
Amlodipine Besylate351$2,251
Losartan Potassium171$2,162
Potassium Chloride105$2,079

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$22$62,00649 claims
AstraZenecaBrilinta, Farxiga$17,475$25,89530 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 760 cardiovascular disease providers in Michigan.

Other cardiovascular disease in Jackson

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →